Tyrosine kinase inhibitors for treating MET mutation-positive metastatic non-small-cell lung cancer

Published on 31 Aug 2022
Last Updated on 31 Aug 2022

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Tepotinib 225 mg tablet

for treating metastatic mesenchymal epithelial transition exon 14 skipping (METex14sk) mutation-positive non-small-cell lung cancer (NSCLC) in line with specific clinical criteria.

Funding status

Tepotinib 225 mg tablet is recommended for inclusion on the MOH Cancer Drug List (CDL; MAF with MediShield Life monthly claim limit of $1,600) for the abovementioned indication from 1 September 2022.    

CDL listing does not apply to any formulations or strengths of capmatinib for treating metastatic METex14sk mutation-positive NSCLC.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.

Tyrosine kinase inhibitors for MET mutation-positive metastatic NSCLC (31 Aug 22) [PDF, 133 KB]

Treatments for MET exon 14 skipping mutated metastatic NSCLC PES (31 Aug 22) [PDF, 83 KB]